Nation's Largest Medical Specialty Organization Issues New Guideline For Screening For Osteoporosis In Men Osteoporosis is often viewed as a women's
health issue, but one in 16 men over 65 suffers from the disease, and few men are currently tested or diagnosed. Because of the aging population, a dramatic increase in osteoporosis among men is expected in the near future. New recommendations from ACP call for physicians to screen for osteoporosis in older men, especially those over the age of 65.
Source: www.medicalnewstoday.comCannabis - Decision To Reclassify Is Wrong, Says Mental Health Charity Rethink, UK Mental
health charity Rethink has today expressed its disappointment at the government's decision to reclassify cannabis as a class B drug. Paul Corry, director of public affairs, says: "The government has made a mistake by choosing to reclassify cannabis as a class B drug. This decision goes against all the evidence.
Source: www.medicalnewstoday.comNKTR-118 Shows Substantial Oral Bioavailability And Extended Half-Life In Phase 1 Clinical Data Presented At American Pain Society Meeting New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics (Nasdaq: NKTR) this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida. In this multiple-dose Phase 1 study, oral NKTR-118 was shown to have substantial oral bioavailability with rapid absorption and an extended half-life that is up to ten times the known half-life of unPEGylated naloxone.
Source: www.medicalnewstoday.comSchizophrenia - Risperidone Long-Acting Injection Extends Time To Relapse Compared To Oral Quetiapine A new study, presented for the first time at an international psychiatric meeting, examined the time to relapse in patients with schizophrenia treated with risperidone long-acting injection (RLAI) or oral quetiapine. The data show that the mean time free from relapse for patients treated with RLAI was statistically longer than those treated with quetiapine (607 days RLAI versus 533 days with quetiapine, p
Source: www.medicalnewstoday.comDepression Treatments Reviewed By NeuroInvestment NeuroInvestment announced the release of its May issue, which reviews novel treatments being developed for depression. Even though depression can be argued to be the success story of psychopharmacology, the current array of largely similar monoamine-targeting
drugs leave 30% of patients without adequate relief, and incur significantly aversive side effects for the majority.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 6:00 AM
